Nattokinase Dosages and Thrombotic Risks in Children with MIS-C
Common Dosages in Studies
Many studies use doses ranging from 2,000 to 10,000 FU per day. These studies examine effects like improved blood circulation, reduced blood pressure, and enhanced fibrinolytic activity.
High-Dose Studies:
The highest dosage noted in available studies is around 10,800 FU per day. This study focused on the effects of Nattokinase on atherosclerotic progression and lipid profiles in the bloodstream.
General Findings
Nattokinase is praised for its potential cardiovascular benefits, particularly in improving blood flow and reducing clotting. However, the effects at very high doses (such as 40,000 FU) are not documented, which suggests a gap in the research or potential safety concerns at such high levels.
Children
Even children with Multisystem Inflammatory Syndrome (MIS-C) can develop thrombosis or blood clots. This complication is part of the broader inflammatory response that characterises MIS-C, which can affect various organ systems, including the cardiovascular system.
Evidence and Findings
Thrombotic Complications
Incidence: Thrombotic events, including deep vein thrombosis (DVT), pulmonary embolism, and other forms of thrombosis, have been reported in children with MIS-C.
Mechanism: The hyperinflammatory state in MIS-C can lead to endothelial injury, activation of the coagulation cascade, and formation of clots. Elevated levels of inflammatory markers like D-dimer are often observed, indicating a heightened risk of thrombotic events.
Clinical Studies
CDC: The Centers for Disease Control and Prevention (CDC) acknowledges that thrombotic complications are part of the clinical spectrum of MIS-C. They recommend monitoring and, in some cases, using anticoagulants in managing these patients.
Journal of the American College of Cardiology: A study published in this journal detailed cases of children with MIS-C who developed thrombotic complications, emphasising the importance of early recognition and management of these events.
New England Journal of Medicine (NEJM): Reports in the NEJM have documented the occurrence of thrombotic events in MIS-C, supporting the use of anticoagulants as part of the treatment regimen for affected children.
Treatment Guidelines
Anticoagulants: Given the risk of thrombosis, many treatment protocols for MIS-C include anticoagulants like enoxaparin or aspirin to mitigate this risk.
Monitoring: Regular monitoring of coagulation markers, such as D-dimer and fibrinogen levels, is recommended to assess the risk and presence of thrombotic events.
Sources
- CDC - Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C): CDC MIS-C Guidelines
- Journal of the American College of Cardiology: Thrombotic Complications in MIS-C
- New England Journal of Medicine: Clinical Characteristics of MIS-C
Conclusion
Thrombotic complications are a significant concern in children with MIS-C, and early recognition and management are crucial.
The use of anticoagulants and close monitoring of coagulation markers are standard practices to prevent and treat thrombosis in these patients. The ongoing research and clinical observations continue to refine the best practices for managing these serious complications.
